| Name | Title | Contact Details |
|---|
Visible Measures is the real-time video content marketing platform of choice. Consumers today have more choice than ever before, so we make it our business to understand what makes them choose one video over another. We connect these people with branded videos so they can watch, discuss, and share them. With the broadest video data footprint in the industry, global brands and publishers rely on us to engage audiences with relevant video across channels and devices. You may know our proprietary data and technology, which powers top video charts for Advertising Age, Variety, Automotive News, and iMedia Connection, among others. We also hold the world’s first accredited viewership metric.
Nearmap Limited is an Australian aerial imagery technology and location data company that provides frequently-updated, high-resolution aerial imagery of 88% of Australias population, 68% of the United States population, and 72% of the New Zealand popu...
Tracsis is a technology company that provides software, hardware, data analytics/GIS and services for the rail, traffic data and wider transport industries. They specialize in solving a range of data capture, reporting and resource optimization problem...
Blockchain.com is connecting the world to the future of finance. We are the most trusted and fastest growing crypto company, helping millions across the globe – from single individuals to the largest institutions – have an easy and safe way to buy, sell and store cryptocurrency. Known as the world`s most popular crypto wallet, Blockchain.com is on a path to revolutionizing the $14T financial services industry. Blockchain.com is backed by leading investors including Lightspeed Venture Partners and Google Ventures.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.